Emergent Biosolutions, Inc. (NYSE:EBS) EVP Adam Havey sold 7,885 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $37.06, for a total transaction of $292,218.10. Following the completion of the sale, the executive vice president now directly owns 33,931 shares in the company, valued at $1,257,482.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Shares of Emergent Biosolutions, Inc. (EBS) traded up 2.13% during midday trading on Tuesday, reaching $38.44. 205,373 shares of the company were exchanged. The stock has a market capitalization of $1.58 billion, a P/E ratio of 24.48 and a beta of 1.23. The company has a 50 day moving average price of $35.89 and a 200-day moving average price of $32.36. Emergent Biosolutions, Inc. has a 12-month low of $24.47 and a 12-month high of $38.44.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.26 by ($0.13). The firm had revenue of $100.77 million for the quarter, compared to analysts’ expectations of $111.57 million. Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. The firm’s revenue was up 10.4% on a year-over-year basis. During the same period last year, the company earned ($0.05) earnings per share. On average, analysts forecast that Emergent Biosolutions, Inc. will post $1.54 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.themarketsdaily.com/2017/09/12/adam-havey-sells-7885-shares-of-emergent-biosolutions-inc-ebs-stock.html.
EBS has been the topic of a number of recent analyst reports. BidaskClub raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Friday, August 25th. Zacks Investment Research downgraded shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Emergent Biosolutions has an average rating of “Buy” and an average price target of $44.00.
Several institutional investors and hedge funds have recently modified their holdings of the company. Public Employees Retirement System of Ohio raised its holdings in shares of Emergent Biosolutions by 2.6% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 36,866 shares of the biopharmaceutical company’s stock worth $1,250,000 after acquiring an additional 917 shares in the last quarter. Piedmont Investment Advisors LLC purchased a new stake in shares of Emergent Biosolutions during the 2nd quarter worth approximately $255,000. Ameritas Investment Partners Inc. raised its holdings in shares of Emergent Biosolutions by 23.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 587 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Emergent Biosolutions by 2.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 631,304 shares of the biopharmaceutical company’s stock worth $21,409,000 after acquiring an additional 15,314 shares in the last quarter. Finally, Macquarie Group Ltd. raised its holdings in shares of Emergent Biosolutions by 0.8% during the 2nd quarter. Macquarie Group Ltd. now owns 25,969 shares of the biopharmaceutical company’s stock worth $881,000 after acquiring an additional 197 shares in the last quarter. 85.44% of the stock is currently owned by institutional investors and hedge funds.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.